Benefit/AFF risk ratio favors 3–5 years of treatment
If denosumab is stopped, it should be replaced with another osteoporosis treatment
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy